A 52-year-old African American male with developmental disorder, insomnia, impulse control disorder, aphasia, cognitive communication deficit, and epilepsy, currently taking valproic acid (250 mg/5 mL) 15 mL three times daily, risperidone 1 mg nightly, aripiprazole 10 mg daily, and melatonin 6 mg as needed, presents with a recent increase in aggressive behavior; what management steps should be taken?

Management of Increased Aggressive Behaviors

First, check valproic acid levels immediately and assess for valproate-induced hyperammonemia, as this patient is on a high dose (2250 mg/day) and hyperammonemia can present with behavioral changes including aggression. 1, 2

Immediate Assessment Steps

Critical laboratory evaluation:

• Valproic acid serum level (therapeutic range 50-100 μg/mL)
• Ammonia level (hyperammonemia can cause behavioral deterioration)
• Complete metabolic panel including liver function tests
• Complete blood count with platelets

Clinical evaluation specifics:

• Onset timing of aggression relative to medication changes
• Seizure control status (breakthrough seizures can manifest as behavioral changes)
• Sleep quality assessment (insomnia worsening can exacerbate aggression)
• Signs of akathisia or extrapyramidal symptoms from antipsychotics

Medication Optimization Strategy

Antipsychotic Polypharmacy Concern

This patient is on dual antipsychotic therapy (risperidone 1 mg + aripiprazole 10 mg), which is problematic. The evidence shows:

• Risperidone at 1 mg nightly is within recommended dosing for behavioral control (guidelines suggest 0.25-3 mg/day for agitation/combativeness) 1
• However, combining two antipsychotics increases risk without clear benefit 3
• Aripiprazole FDA labeling specifically warns about agitation, irritability, hostility, and aggressiveness as potential adverse effects 4

Recommended action: Consider discontinuing aripiprazole first, as it may be paradoxically contributing to aggression rather than controlling impulse disorder. The FDA label explicitly lists "aggressiveness, impulsivity, irritability, and hostility" as reported adverse effects in patients treated with aripiprazole 4.

Valproic Acid Considerations

The current valproic acid dose (2250 mg/day) is high and requires monitoring:

• Valproic acid itself can be used as a mood stabilizer for agitation at therapeutic levels (40-90 μg/mL) 1
• However, supratherapeutic levels or hyperammonemia cause behavioral deterioration 2
• In patients with intellectual disability and epilepsy, valproic acid is preferred over phenytoin/phenobarbital due to lower behavioral adverse effects 3
• If levels are therapeutic and ammonia normal, valproic acid is likely helping, not harming

Risperidone Optimization

If aggression persists after aripiprazole discontinuation:

• Current dose (1 mg HS) can be increased to 2-3 mg/day in divided doses 1
• Consider splitting to twice-daily dosing (e.g., 1 mg BID) for better 24-hour coverage of aggressive behaviors
• Monitor for extrapyramidal symptoms, which increase at doses >2 mg/day 1
• Risperidone has the strongest evidence for controlling "severe psychomotor agitation and combativeness" in patients with developmental disorders 1, 5

Alternative Pharmacologic Options

If risperidone optimization fails:

1. Quetiapine 25 mg PO BID (starting dose), titrate to 200 mg BID maximum

   • More sedating profile may help with insomnia
   • Less likely to cause extrapyramidal symptoms 6, 1
   • Beware orthostatic hypotension 1

2. Olanzapine 2.5-5 mg PO daily (usually at bedtime)

   • Generally well tolerated 1, 6
   • May cause metabolic effects with long-term use
   • Dual benefit for aggression and sleep

3. Consider adding trazodone 25-50 mg for insomnia if melatonin insufficient

   • May reduce agitation as adjunctive therapy 1
   • Addresses sleep component which can worsen behavioral symptoms

Non-Pharmacologic Interventions

Essential concurrent measures:

• Behavioral analysis to identify aggression triggers
• Environmental modifications to reduce stimulation
• Structured daily routine with consistent sleep-wake schedule
• Family/caregiver education on de-escalation techniques

Monitoring Plan

Weekly for first month:

• Behavioral rating scales (document aggression frequency/severity)
• Vital signs and weight
• Movement disorder assessment

Monthly thereafter:

• Metabolic panel (glucose, lipids if on atypical antipsychotics)
• Valproic acid level every 3-6 months
• Liver function tests every 6 months

Critical Pitfalls to Avoid

• Do not add benzodiazepines routinely - they can cause paradoxical agitation in ~10% of patients with developmental disorders 1
• Avoid typical antipsychotics (haloperidol, chlorpromazine) - 50% risk of tardive dyskinesia after 2 years in this population 1
• Do not assume aggression is purely behavioral - always rule out medical causes (pain, infection, constipation, medication toxicity)
• Avoid rapid medication changes - allow 4-8 weeks to assess response unless safety concerns 1